IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
-0.81%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q1 FY2025

Full document

Opus Genetics, Inc. Form 8-K Summary

Business Context and Reporting Period

Opus Genetics, Inc. (Nasdaq: IRD), a Delaware corporation, filed this Current Report on Form 8-K on January 13, 2025. The filing discloses the establishment of a new at-the-market equity issuance program to raise capital for general corporate purposes, including preclinical studies, clinical trials, and the advancement of product candidates.

Key Financial Metrics

This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metric disclosed is the potential capital raise:

  • Offering Size: Up to $40,000,000 in aggregate offering price.
  • Commission: 3.0% of gross sales proceeds payable to the sales agent.
  • Prior Program Sales: Approximately $26.4 million in gross sales price was raised under the terminated prior distribution agreement.

Material Changes

The Company entered into a new Sales Agreement with Leerink Partners LLC on January 13, 2025, replacing its prior program. Consequently, the Company terminated its Capital on DemandTM Sales Agreement dated March 11, 2021, with JonesTrading Institutional Services LLC.

Guidance, Outlook, and Risks

Use of Proceeds: Net proceeds will be used for general corporate purposes, specifically preclinical studies, clinical trials, and product advancement. Pending application, funds will be invested in interest-bearing, investment-grade securities, certificates of deposit, or government securities.

Management Discretion: Management retains broad discretion regarding the timing and application of net proceeds, as specific uses cannot be specified with certainty at this time.

Risks: The filing notes that the report does not constitute an offer to sell shares in jurisdictions where such an offer would be unlawful prior to registration. The success of the offering depends on market conditions and the Company's instructions regarding price, time, and size limits.

Investor Verification Checklist

  • Verify the current share price and potential dilution impact of selling up to $40 million in shares.
  • Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and pricing parameters.
  • Confirm the Company's current cash runway and immediate capital needs relative to the $40 million target.
  • Monitor future filings for actual proceeds raised and specific allocation of funds to clinical trials.